Magellan Midstream Partners LP (MMP) Stock

BOTOX® Cosmetic is the first neurotoxin approved in China for the treatment of masseter muscle prominence (MMP), the largest global market for MMP. Approval supported by well-established safety profile and robust clinical trials demonstrating BOTOX® Cosmetic is effective in reducing the prominence of the masseter muscle.

ONEOK announced a merger with Magellan Midstream Partners, one of the largest deals in the energy sector, which will significantly increase OKE's EBITDA. The Company has consistently grown its EPS by 14% annually through acquisitions, and its yield above 5% makes it an enticing investment. Despite concerns about debt levels and achieving expected synergies from the merger, OKE's resilience and strategic ambitions make it a buy.

With Wall Street ending a tumultuous week amid a hawkish Fed outlook, investors should invest in safe stocks like Magellan Midstream Partners (MMP), Trinity Capital (TRIN), Runway Growth Finance (RWAY) & Postal Realty Trust (PSTL).

The proposed transaction involves the acquisition of all outstanding units of Magellan Midstream (MMP) by ONEOK through a mixture of cash and stock.

Magellan Midstream Partners' unitholders on Thursday voted in favour of the U.S. pipeline operator's planned sale to larger peer ONEOK Inc for $18.8 billion.

The $19 billion transaction was was approved at a unit holder meeting Thursday, despite some investor opposition to the deal.

Does Magellan Midstream Partners (MMP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Magellan Midstream Partners has pressed its case for the $19 billion deal, citing strategic benefit and downplaying tax issues ahead of next week's vote.

When a company agrees to be acquired, there's often a premium built into the takeout price. Investors usually bid a stock up toward the purchase offer.